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Abstract: Ekbom disease (EKD), formerly known as restless legs syndrome (RLS) has affected 
and bothered many people over the centuries. It is one of the most prevalent neurological disorders 
in Europe and North-America, affecting about 10% of the population. The main characteristics are 
the strong urge to move, accompanied or caused by uncomfortable, sometimes even distressing, 
paresthesia of the legs, described as a “creeping, tugging, pulling” feeling. The symptoms often 
become worse as the day progresses, leading to sleep disturbances or sleep deprivation, which leads 
to decreased alertness and daytime functions. Numerous studies have been conducted assessing 
the efficacy of dopaminergic drugs, opioids, and other pharmacologic agents in alleviating EKD 
symptoms. However, there is also a growing body of evidence demonstrating the effectiveness of 
nonpharmacologic treatments including life style changes, physical activity programs, pneumatic 
compression, massage, near-infrared light therapy, and complementary therapies. The working 
mechanisms behind these alternatives are diverse. Some increase blood flow to the legs, therefore 
reducing tissue hypoxia; some introduce an afferent counter stimulus to the cortex and with that 
“close the gate” for aberrant nerve stimulations; some increase dopamine and nitric oxide and 
therefore augment bio-available neurotransmitters; and some generate endorphins producing 
an analgesic effect. The advantages of these treatments compared with pharmacologic agents 
include less or no side effects, no danger of augmentation, and less cost.
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Introduction
Restless legs syndrome (RLS) has affected and bothered many people over the centu-
ries.1 In 1685, patients with RLS were first described as suffering as if going through 
torture.2 It took another 260 years before the first detailed description of the medical 
traits of RLS was published.2 Shortly thereafter, in 1960, Ekbom defined all clinical 
features and coined the term restless legs syndrome.1 In his honor, the name of this 
pathology was recently changed to Ekbom disease (EKD). EKD is one of the most 
prevalent neurological disorders in Europe and North-America, affecting about 10% of 
the population, with women being afflicted almost twice as often as men.3,4 The usual 
presentation of this condition is characterized by a strong urge to move, accompanied 
or caused by uncomfortable, or even distressing paresthesia of the legs, described as 
a “creeping, tugging, pulling” feeling.1 The symptoms often become worse as the day 
progresses, leading to sleep disturbances or sleep deprivation, which further result in 
impairment of alertness and daytime functions.5
Ekbom disease is generally classified as “primary” (genetic or idiopathic) or 
“secondary” (related to other medial or neurological disorders) or it can arise from Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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a combination of factors.6 The treatment for secondary EKD 
is aimed mostly at dealing with the underlying conditions. 
For example, low serum iron levels are associated with 
EKD,1,7–9 and it has been shown that administration of iron 
can decrease EKD symptoms.10 Other pathologies such as 
diabetes mellitus, end stage renal disease, vitamin B12 defi-
ciency, folate deficiency,9 Parkinson’s disease,11 uremia, and 
fibromyalgia12 have been associated with EKD. The options 
discussed in this paper will be most beneficial for the treat-
ment of primary EKD.
The diagnosis is based primarily on the complaints of 
the patient, as there are no biomarkers, classic measurable 
clinical findings, conclusive blood assays, or radiological 
and sleep studies that can clearly implicate EKD. A long-
needed, standardized way to identify and substantiate EKD 
was developed by the International Restless Legs Syndrome 
Study Group (IRLSSG).13 It is a four-question survey that 
explores 1) whether the subjects have an urge to move their 
legs, 2) whether the symptoms begin or worsen during 
periods of inactivity, 3) whether the urge to move is at least 
partially relieved by movement, and 4) whether this urge to 
move is worse in the evening or night.13 Affirmative answers 
to all four questions means that the criteria for EKD diagnosis 
are met. The IRLSSG also defined three supportive features; 
they are: family history, presence of periodic limb movement, 
and the response to dopaminergic treatment.13 While they are 
not essential to the diagnosis of EKD, their presence can help 
resolve diagnostic ambiguity.
Diagnosis and evaluation of EKD
Different tools are available that measure severity of the 
symptoms and their impact on a person’s life and track a 
person’s progress or decline: the IRLSSG rating scale, Johns 
Hopkins RLS severity scale, RLS quality of life instrument, 
Epworth sleepiness scale, and the fatigue visual analog 
scale.14 The IRLSSG rating scale15 is a 10-question scale, 
developed by the IRLSSG as a means of assessing the sever-
ity of EKD and of tracking changes in symptoms associated 
with this pathology.15 It assesses the impact of EKD in a 
patient’s quality of life and function. Each question can be 
answered with one of five possible answers with attached 
points (0–4) according to severity. Therefore, a maximal 
score of 40 can be obtained. Generally, an IRLSSG rating 
scale score between 1 and 10 corresponds to “mild”, 11–20 
“moderate”, 21–30 “severe”, and 31–40 “very severe” EKD. 
The Johns Hopkins RLS severity scale was the first pub-
lished clinical scale to assess EKD severity.16 It   consists of 
only one item, which asks for the time of day the symptoms 
start. Four possible answers are linked to scores as follows: 
0 = no symptoms, 1 = bedtime-only symptoms (after or 
within an hour of going to bed), 2 = evening and bedtime 
symptoms (starting at or after 6 pm), and 3 = day and night 
symptoms (starting before 6 pm). This scale was mostly 
created for screening and epidemiological research.16 The 
RLS quality of life instrument17 consists of 17 questions 
assessing domains such as daily function, social function, 
sleep quality, and emotional wellbeing. For each question, 
the possible answers range from “never” to “very often”, 
with an attached score ranging from 5 to 1 respectively. The 
scores for the different domains are calculated   separately. 
The Epworth sleepiness scale18 is used to determine the 
level of daytime sleepiness by giving the patient eight situ-
ations and asking for the chance of dozing off or falling 
asleep during those scenarios. The four possible answers 
are each linked to 0–3 points respectively. A score of 10 
or more is considered “sleepy”, a score of 18 or more is 
considered “very sleepy”. The fatigue visual analog scale 
is a unidimensional fatigue measurement. Here the patient 
has to mark his/her level of experienced fatigue (during a 
determined time frame) on a 10-cm line. Its anchors are 
“no fatigue” on one side and “worst possible fatigue” on 
the other.
Pathogenesis
Compounding the fact that EKD has no measurable signs 
is the uncertainty about its patho-genesis. In the 1940s and 
1950s it was assumed that EKD stemmed from vascular 
disturbances.2 This theory came under disfavor when it 
was observed that patients with EKD responded well to 
dopaminergic agents, such as Levodopa, and dopamine 
agonists. Levodopa, a precursor of dopamine that can cross 
the blood–brain barrier and is metabolized in the brain into 
dopamine, is also used to treat Parkinson’s disease, a low 
dopamine condition. It is this similar treatment response 
between Parkinson’s disease and EKD that resulted in 
speculations that these two disorders might be related in their 
origins.19 Different hypotheses on EKD etiology – or lack 
thereof – prompt different treatment suggestions: the ones 
trying to manage the symptoms by changing the lifestyle, the 
ones tackling the peripheral nervous system and blood flow, 
and the ones addressing dopamine regulation in the central 
nervous system via pharmaceuticals.
Hundreds of articles exist on the treatment of EKD with 
pharmaceuticals. Many authors recommend exercises or 
other adjunct modalities for the treatment of EKD,6,12,20–27 
but there are not many studies assessing the efficacy of Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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other treatments. I found: one systematic review assessing 
efficacy of acupuncture in the treatment of EKD;28 three 
randomized controlled trials (RCTs) (one assessing a 
12-week exercise program,29 one assessing a pneumatic 
compression device worn daily,14 and one evaluating the 
efficacy of near-infrared [NIR] light   treatment30); three 
prospective interventional studies evaluating the efficacy 
of physical exercise,31 pneumatic compression device,32 
and NIR light;33 and three case reports assessing the 
effectiveness of massage therapy,34 pneumatic compression 
device,35 and NIR light.36 All of these studies concluded that 
EKD symptoms significantly decreased after using these 
interventions. This article will focus on treatment options 
involving nonpharmacological alternatives (Figure 1). For 
most relevant research see Table 1.
Treatment options
Lifestyle
Lifestyle changes as an intervention for EKD include improv-
ing sleep quality by controlling sleep times and by reducing 
caffeine and alcohol consumption.6,7,29,37 Mental activity, 
such as reading, card games, or computer work, has been 
suggested to be successful in decreasing EKD symptoms.38 
The success of these choices is not well documented.
Physical activity
Epidemiologic evidence indicates that lack of exercise is a 
strong predictor of and a significant risk factor for EKD.39 
Physical activity and exercise have long been the only 
nonpharmacological treatment options available to EKD 
sufferers. In fact, by definition, EKD is the urge to move 
that is at least partially relieved by movement.13 It was 
recently shown in a RCT that a 3-day per week exercise 
program of aerobic and lower-body resistance training 
significantly decreased EKD symptom severity.29 While the 
authors did not attempt to explain the reasons for why or 
how exercise was successful in decreasing EKD severity, 
one can surmise that the increase in blood flow brought 
on by activity40 could play a role. Shear forces between 
the inner wall of the endothelium and the moving blood 
stimulate the enzyme nitric oxide (NO) synthase.41,42 Once 
generated, NO diffuses into the smooth muscle of the 
endothelium and then quickly diffuses through the muscle 
tissue of the blood vessel. There it activates guanylate 
cyclase, which then activates the second messenger cGMP 
(cyclic guanosine monophosphate). Several steps follow 
and culminate in the relaxation of smooth muscles in the 
blood vessel. This leads to vasodilation and consequently 
to increased local blood flow.43–45 NO is also scavenged by 
hemoglobin in the blood.46 Under low pO2 (partial pressure 
of oxygen) conditions, during physiologic “hypoxia”, the 
red blood cells release NO to increase blood flow.46 Another 
possible reason for the success of exercises in the treatment 
of EKD symptoms could be the exercise-induced release 
of endorphins.47 Endorphins are endogenous opioid poly-
peptide compounds, produced by the pituitary gland and 
hypothalamus that produce analgesia and a sense of well-
being.48 Another central change occurring with exercise, 
and therefore a further potential mechanism with which 
physical activity can aid in decreasing EKD symptoms, is 
the increased release of dopamine.49 It has been shown that 
especially during high-intensity exercise dopaminergic neu-
rotransmission changes.49 A study assessing the incidence 
of EKD during sleep following acute physical activity in 
spinal cord injury subjects47 found a significant reduction 
in EKD as measured by polysomnographic sleep param-
eters and decrease of leg movements. The authors reject 
the hypothesis that dopamine deficiency could be involved 
in the symptoms felt by spinal cord-injured EKD sufferers 
because of their spinal cord trauma. Instead, they suggest 
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Figure  1  eKD  treatment  options  and  their  potential  working  mechanisms. 
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that the release of endorphins after physical activity may 
be the cause for the symptom reduction.
Pneumatic compression devices
One of the first modern-day (1940s and 1950s) hypothesis 
attempting to explain the etiology of EKD symptoms associated 
it with decreased blood flow.35 Ekbom,1 too, believed that vaso-
dilators given to EKD sufferers would decrease the   symptoms. 
The vascular hypothesis was later neglected but revived in 
2005, when increased vascular blood flow with pulsed com-
pression devices was shown to significantly decrease EKD 
symptoms in six patients.35 Other studies have followed14,32 
confirming these findings. The pneumatic compression devices 
were applied to the thigh and leg regions; the parameters used 
were 40 cm H2O of air pressure intermittently for 1 hour. It is 
hypothesized that vascular compression stimulates the release 
of endothelial mediators (ie, NO)50 that then can modulate EKD 
symptoms. It is also possible that intermittent compression, 
which enhances venous and lymphatic drainage, could relieve 
subclinical ischemia.14 These findings are not surprising, taking 
into account that a high prevalence (36%) of EKD in patients 
present with chronic venous disorder.51
Massage
Tactile and temperature stimulation, including massage or 
hot baths, can also be successful in decreasing symptoms 
associated with EKD.38,52 While many authors mention these 
modalities as potential treatment options and   numerous 
websites recommend them, there is a paucity of scientific 
trials confirming their efficacy. However, one case report34 
describes a 3-week massage regimen that decreased EKD 
symptoms significantly. This massage was given for 45 min-
utes twice a week using techniques such as Swedish mas-
sage (effleurage, petrissage), myofascial release, friction to 
tendinous attachments, stretches, and direct pressure to hip 
and lower extremity muscles. The symptoms returned after 
2 weeks post treatment.34 The author suggests that the natural 
release of dopamine following massage could have been 
responsible for the amelioration of the symptoms. Massage 
has shown to increase dopamine levels in urine by an aver-
age of 28% in different conditions.53 Another speculation 
on the working mechanism of massage in the treatment of 
EKD is the counter stimulation it provides to the cerebral 
cortex. The tactile stimulation could supersede afferent 
input associated with EKD symptoms or at least partially 
modulate the perception of discomfort in the legs.54 Another 
explanation involving the central nervous system is the pos-
sibility that tactile and temperature stimulations traveling 
in the spinothalamic tract may modulate neural activity in 
the thalamus. Bucher et al55 have shown that activation of 
the thalamus is associated with sensory leg discomfort in 
idiopathic EKD patients. A fourth explanation could be the 
Table 1 Most relevant research
Treatment Study Study design Number 
of patients  
in treatment group
Duration of study Measurement tool
exercise Aukermann et al29 Randomized, 
controlled
11 Tiw for 12 weeks iRLSSG scale
PCD Lettieri and 
eliasson14
Prospective, 
randomized, double 
blind, controlled
21 QD for 4 weeks iRLSSG scale, JHRLS, RLS-QLi, 
eSS, Fatigue visual analog scale
eliasson and 
Lettieri32
Uncontrolled, 
prospective 
interventional
9 QD for 3 months iRLSSG scale, RLS-QLi, eSS
Rajaram et al35 Case series 6 QD for 35 days iRLSSG scale
Massage Russel34 Case report 1 Biw for 3 weeks Functional rating index, digital 
symptom intensity scale
NiR Mitchell et al30 Randomized 
controlled
17 Tiw for 4 weeks iRLSSG scale
Mitchell et al33 Observational 
uncontrolled
24 Tiw for 4 weeks iRLSSG scale
Mitchell36 Case report 1 Tiw for 4 weeks iRLSSG scale
Acupuncture Cui et al28 Systematic review Two studies with  
120 and 48 patients
One treatment each 
study
“Ordinal outcome”, vAS, longest 
and shortest duration of RLS 
symptoms in 1 month before 
and after treatment
Abbreviations: Biw, twice per week; eSS, epworth sleepiness scale; iRLSSG, international Restless Legs Syndrome Study Group; JHRLS, Johns Hopkins restless legs severity 
score; NiR, near-infrared light; PCD, pneumatic compression devices; QD, once per day; RLS-QLi, restless legs syndrome quality of life instrument; Tiw, three times per week.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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mechanically induced increase of circulation. Massage moves 
venous blood to the heart, transporting nutrients to the tissue 
and metabolic products away from the tissue. Consequently, 
the potentially de-oxygenated tissue receives oxygen which 
then can restore vascular blood gas balance.
NiR light
NIR light has been used in the treatment of neuropathy to 
increase sensation and decrease pain,56–63 wound healing,64,65 
and more recently in the treatment of EKD.30,33,36 The 
proposed mechanism of NIR light therapy is its ability to 
generate NO in the endothelium by activating the enzyme 
nitric oxide synthase (NOS)-3,66 similar to exercise-induced 
NOS-3 activation. “Intensive illumination”, such as during 
NIR light treatment, can also free NO from hemoglobin and 
thus make it bio-available.67 The discomfort that accompa-
nies the EKD-related urge to move could be caused by the 
lack of tissue oxygen, which would be offset by an increase 
in blood flow. The urge to move may be a subconsciously 
driven mechanism to augment blood flow and tissue per-
fusion. Moving, such as walking or rubbing of legs,40,68 
diminishes EKD symptoms as it enhances   circulation. 
Therefore, treatment with a vasodilator, such as NIR-
induced NO, could conceivably temporarily decrease the 
symptoms associated with EKD. Even a prolonged reduc-
tion of symptoms (up to a couple of weeks post treatment) 
has been observed.30 This was explained with a potential 
systemic effect of light therapy.69 This systemic effect could 
be responsible for either continued NO production or other 
changes in the tissue, leading to diminished symptoms. 
Additionally, NO has influence on neurotransmission.44 
It is one of the substances that influences nerve impulse 
transfer as it assists in converting nerve signals as they 
cross synapses.44 This quality of NO might also be involved 
in reducing symptoms associated with EKD. All things 
considered, NIR could positively impact EKD symptoms 
by numerous methods.
Complementary and alternative medicine
The use of complementary and alternative medicine is 
another option available to EKD sufferers. Vitamins 
rank high on the list.70 Their use in the treatment of EKD 
symptoms is based on the hypothesis that the unpleasant 
EKD sensations come from the stimulation of dysfunc-
tional peripheral nerve fibers found along blood vessels.71 
  Vitamins E and B are associated with the nervous system. 
Intake of daily 300 mg vitamin E for 1 week may stabilize 
peripheral blood circulation and decrease symptoms.71 
Vitamin B12 intake may support the stability of nerve 
fibers,   preventing excessive sensitivity and add further 
to the decrease of EKD symptoms.71 Multivitamins and 
vitamin C intake are also used to decrease EKD symptoms, 
followed by glucosamine, zinc, folic acid, vitamin D, and 
magnesium.70 Nonbiologically based treatment options 
include prayer, meditation, and music.70 Acupuncture is 
also considered an alternative medicine. It is an ancient 
Chinese medical therapy used in the prevention and treat-
ment of disease.28 It involves inserting needles into specific 
points on the body. A review article28 studied several kinds 
of acupuncture methods, such as body acupuncture, auricu-
lar acupuncture, scalp acupuncture, electro-acupuncture, 
laser acupuncture, acupressure, and acupoint injection 
therapy for the treatment of EKD symptoms. The authors 
concluded that the evidence that acupuncture is an effective 
treatment option for EKD sufferers is still insufficient to 
support the hypothesis that acupuncture is more effective 
than no treatment or other therapies.
Placebo
As with all medication and treatment, the power of placebo 
must not be underestimated. The Latin word “placebo” 
means: “I shall please”, indicating a certain conscious expec-
tation from a treatment. This means, that the context and 
environment of the treatment plays an important role in the 
patient’s improvement potential.72 A recent meta-analysis73 
assessing the placebo effect in EKD treatment studies found 
a considerable placebo response associated with EKD treat-
ment. On average, more than one-third of EKD subjects 
experience a major improvement of EKD symptoms while 
receiving placebo treatment. The authors propose that the 
reason for this might be related to EKD’s unique respon-
siveness to dopaminergic agents and opioids – both systems 
implicated in the placebo response.
Conclusion
This article focused on treatment options for mainly pri-
mary EKD, involving nonpharmacological alternatives. 
Recommendations for patients with EKD suggest that 
certain life style changes, exercise, treatment modalities, 
as well as alternative medicine are linked to a decrease 
of symptoms associated with EKD. There is no research 
assessing the possibility of an enhanced effect of these 
modalities when applied together. It is very likely that the 
pathogenesis of this condition is multifaceted and therefore 
demands a comprehensive treatment approach. Because of 
the possible myriad side effects when treating EKD with Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  pharmaceuticals, the treatment options named above should 
be given consideration.
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